| |
Rescue studies are not meant to be taken lightly – logistical hurdles and communication challenges are aplenty. Despite this, Premier Research doesn’t back down. See how our unique advantages helped a sponsor recover a Phase 1 oncology trial: Learn More
Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsOct 11, 2023 |
|
Thursday, October 12, 2023 | 11am ET / 8am PT A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks? In this webinar, leaders in industry and academia discuss their experiences using innovative tools to study and develop therapeutics against influenza, SARS-CoV-2, dengue viruses, and more. Register now. 
|
|
| By Annalee Armstrong Things were going pretty well in the NASH landscape with Madrigal Therapeutics finally submitting a request to approve a treatment, but yesterday the space came crashing back down to reality with the failure of Akero Therapeutics’ med. |
|
|
|
By Gabrielle Masson As Federation Bio fades, Kanvas Biosciences has snapped up two of the biotech’s assets as well as its microbial library and the company’s chief scientific officer Lee Swem, Ph.D., to lead program development. |
By Nick Paul Taylor Merck KGaA is back with another update on the durability of its BTK inhibitor evobrutinib, sharing data that show the effect on relapse rates lasts for at least five years. But with the program on partial clinical hold and phase 3 data imminent, the update may soon be overshadowed by other developments. |
Sponsored by Trinity Life Sciences In a dynamic landscape, three emerging trends have the power to reshape the complexities of pharmaceutical commercialization. |
By Max Bayer Tempest's triplet treatment has shown an advantage over the combo of two Roche drugs for patients with liver cancer in a phase 1/2 trial. The data validate earlier, more preliminary figures reported in April. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By James Waldron A week after entering its lead asset into a phase 2 trial for a type of Crohn’s disease, Agomab Therapeutics has secured $100 million in series C financing to power up its pipeline. |
Sponsored by AnaptysBio AnaptysBio announces top-line data showing rapid clearance of generalized pustular psoriasis (GPP), a rare systemic skin disease |
By Nick Paul Taylor Sana Biotechnology is restructuring and narrowing its focus for the second time in 11 months. With its stock in the doldrums, the cell engineering biotech is pulling back from its in vivo delivery platform and reducing its head count by 29% to stretch its cash runway deeper into 2025. |
By Helen Floersh Scientists for the first time have accomplished long-term kidney transplant from pigs to primates using a clinically-translatable immunosuppression protocol, a potential turning point in their quest to use animal donors to combat a longstanding shortage of transplant organs. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Ben Adams Such is the demand for new anti-obesity drugs that several online companies have begun trying to sell the latest “must-have” meds—but without approval or prescription, and that has irked the FDA. |
By Andrea Park Regulators in the EU are said to be on the verge of handing down an order forcing Illumina to divest Grail, according to multiple reports this week, following a yearslong antitrust battle that’s stretched across the Atlantic. |
By Paige Minemyer Humana CEO Bruce Broussard will step down from the role in the latter part of 2024, and the insurer has already found a successor. |
By Zoey Becker In a phase 3 trial testing the two forms over 24 weeks, the subcutaneous drug measured up to the IV version, Roche said. An approval for the subcutaneous version would open the door to broader usage. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," we explore how video game training can captivate users' minds while also expediting the adoption of new skills and treatments in medicine. |
|
|---|
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
